Shares of AbbVie Inc (NYSE:ABBV) have earned a consensus recommendation of “Hold” from the twenty research firms that are currently covering the company, MarketBeat.com reports. Four analysts have rated the stock with a sell recommendation, seven have given a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $103.68.
ABBV has been the subject of several recent analyst reports. BMO Capital Markets reaffirmed a “sell” rating and issued a $78.00 target price on shares of AbbVie in a report on Wednesday, August 22nd. Wolfe Research initiated coverage on AbbVie in a report on Tuesday, October 23rd. They issued an “underperform” rating for the company. Zacks Investment Research raised AbbVie from a “hold” rating to a “buy” rating and set a $105.00 target price for the company in a report on Monday, October 1st. Credit Suisse Group set a $85.00 target price on AbbVie and gave the company a “hold” rating in a report on Friday, November 2nd. Finally, Barclays reaffirmed a “hold” rating and issued a $90.00 target price on shares of AbbVie in a report on Sunday, November 4th.
In related news, insider Laura J. Schumacher sold 94,140 shares of the company’s stock in a transaction that occurred on Tuesday, December 4th. The stock was sold at an average price of $93.58, for a total value of $8,809,621.20. Following the transaction, the insider now owns 192,398 shares in the company, valued at $18,004,604.84. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Henry O. Gosebruch sold 42,450 shares of the company’s stock in a transaction that occurred on Thursday, November 29th. The shares were sold at an average price of $90.10, for a total value of $3,824,745.00. Following the completion of the transaction, the executive vice president now owns 30,350 shares in the company, valued at approximately $2,734,535. The disclosure for this sale can be found here. 0.07% of the stock is currently owned by corporate insiders.
Several large investors have recently bought and sold shares of ABBV. Capital International Investors lifted its position in shares of AbbVie by 266.4% during the third quarter. Capital International Investors now owns 27,594,648 shares of the company’s stock worth $2,609,902,000 after acquiring an additional 20,063,435 shares in the last quarter. Capital World Investors lifted its position in shares of AbbVie by 74.9% during the third quarter. Capital World Investors now owns 25,359,025 shares of the company’s stock worth $2,398,457,000 after acquiring an additional 10,858,432 shares in the last quarter. Matthew Goff Investment Advisor LLC lifted its position in shares of AbbVie by 9,165.1% during the third quarter. Matthew Goff Investment Advisor LLC now owns 2,226,305 shares of the company’s stock worth $24,029,000 after acquiring an additional 2,202,276 shares in the last quarter. FMR LLC lifted its position in shares of AbbVie by 22.1% during the third quarter. FMR LLC now owns 8,707,454 shares of the company’s stock worth $823,551,000 after acquiring an additional 1,574,495 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. purchased a new stake in shares of AbbVie during the third quarter worth $133,646,000. Hedge funds and other institutional investors own 69.85% of the company’s stock.
Shares of ABBV stock traded down $3.37 during trading on Monday, hitting $86.96. The company’s stock had a trading volume of 6,618,185 shares, compared to its average volume of 6,168,640. The firm has a market cap of $135.88 billion, a PE ratio of 15.53, a P/E/G ratio of 0.84 and a beta of 1.68. The company has a quick ratio of 1.08, a current ratio of 1.20 and a debt-to-equity ratio of 8.70. AbbVie has a 52 week low of $77.50 and a 52 week high of $125.86.
AbbVie (NYSE:ABBV) last released its earnings results on Friday, November 2nd. The company reported $2.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.01 by $0.13. The company had revenue of $8.24 billion during the quarter, compared to analyst estimates of $8.23 billion. AbbVie had a return on equity of 2,006.63% and a net margin of 23.50%. AbbVie’s quarterly revenue was up 17.7% on a year-over-year basis. During the same period in the prior year, the company posted $1.41 earnings per share. On average, research analysts expect that AbbVie will post 7.93 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 15th. Investors of record on Tuesday, January 15th will be paid a $1.07 dividend. This is an increase from AbbVie’s previous quarterly dividend of $0.96. The ex-dividend date of this dividend is Monday, January 14th. This represents a $4.28 annualized dividend and a yield of 4.92%. AbbVie’s dividend payout ratio is presently 68.57%.
AbbVie Company Profile
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune diseases; IMBRUVICA, an oral therapy for treating chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, to treat adults with genotype 1 chronic hepatitis C.
Further Reading: What is the Federal Reserve?
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.